Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$118.5M
15M shares
52-week range
$1.85 – $8.45
91% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
www.cumberlandpharma.comNo one on the platform currently holds CPIX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 470,696 | $1.5M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-08-03 | $1.5000 | 2026-07-31 |
No one on the platform has traded CPIX yet.
$CPIX The likelihood is the trial will accompany AA or will be part of a hybrid/bridge study. In either case, the study will be 18 months or less.
View on StockTwits ↗$CPIX scleroderma is an 8x larger population than dmd. Looking forward to establishing ifetroban as s platform drug. Scleroderma may be more of an impact because it also reflevts RVEF of the heart.
View on StockTwits ↗$CPIX The stock price does not reflect among other things the opportunity in DMD cardiomyopathy given all the trouble at Capricor.
View on StockTwits ↗$CPIX our view, expressed yeaterday, is that the company and shareholders will be maximally rewarded given company sale upon strong dmd data. Lacking scientific, drug development success/experience, and even dollar resources (despite company's proclamation to the contrary) is reason why selling company post positive dmd data, is wisest course of action. Waiting increases risk. No need to wait. A healthy M and A effort needs to be hired and deployed soon to capture reasonable value. Reasonable value may be 500mm, depending on DMD data, Schlerederma data, and "Cancer opporunity"(company language from August 26 earnings call). Pigs in rhis game are almost inevitably slaughtered.
View on StockTwits ↗$CPIX Q2 '26 Earnings Results & Recap Cumberland Pharmaceuticals reported net revenues from continuing operations of $0.17 million for the three months ended June 30, 2026, compared to $0.38 million for the same period in 2025.
View on StockTwits ↗$CPIX normally microcap biotechs are best served by selling into larger, more experienced hands. This is what should be on the minds of management. If DMD data is compelling enough to gain AA, or a hybrid "bridge" pathway, or simply becoming a phase 3 ready asset, the company should sell itself. We expect strong enough DMD data to gain one of these three pathways in next couple months.
View on StockTwits ↗$CPIX Phase 3 DMD is 4 to 5 years long, could be longer if more extended study is needed. will people be willing to wait that long to find out if this drug works or not?
View on StockTwits ↗$CPIX absolute beast remember older posting about DMD prob worth $20+ on that indication alone!
View on StockTwits ↗$CPIX With that much cash this market cap should be double.
View on StockTwits ↗$CPIX highlight of earnings is they have 5 years of cashflow funding to fund these studies. plus a 50 million reserve.
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-8-4-cumberland-pharmaceuticals-inc-stock/ $CPIX Cumberland Pharmaceuticals Earnings Trans
View on StockTwits ↗$CPIX released its three- and six-month 2026 financial results via a press release.
View on StockTwits ↗$CADL I think there are a few very good options for companies approaching the patent cliff. I would count all 3 in the mix to attract interests. $SLS $CPIX
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $38M | — | $-0.55 | $-0.55–$-0.55 | — | 1 |
| 2027 | $38M | +0.0% | $-0.55 | $-0.55–$-0.55 | — | 1 |
| 2028 | $45M | +18.2% | $-0.31 | $-0.31–$-0.31 | — | 1 |
| 2029 | $37M | -18.2% | $-0.22 | $-0.22–$-0.22 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $-0.13 | $-0.20 | -53.8% |
| 2026-05-05 | $-0.13 | $-0.13 | +0.0% |
| 2026-03-03 | $-0.13 | $-0.01 | +92.3% |
| 2025-11-04 | $-0.13 | $-0.06 | +53.8% |
| 2025-05-06 | $-0.01 | $0.16 | +1700.0% |
| 2025-03-04 | $-0.11 | $-0.02 | +81.8% |
| 2024-11-07 | $-0.13 | $-0.02 | +84.6% |
| $30M |
| — |
| LTRNLantern Pharma Inc. | $2.55 | -3.04% | $33M | — |
| LVTXLAVA Therapeutics N.V. | $1.74 | -3.87% | $46M | — |
Source: Financial Modeling Prep · peers by sector/industry